



# HRT

## Easy prescribing guide

Newson Health Menopause Society

The menopause is a normal life event for women and some non binary people — it is not an illness or a medical condition. The life expectancy of women has increased over the past century, this means that on average, women spend over a third of their lives being postmenopausal.

Many suffer in silence and do not realise how effective hormone replacement therapy (HRT) can be at dramatically improving not only their symptoms but their future health too.

# Managing symptoms

Managing people with symptoms of the perimenopause and menopause is a very rewarding aspect of clinical practice. There are now excellent guidelines available, both national and international, for healthcare professionals on the management of the menopause<sup>1-3</sup>. However, worldwide, only a minority of perimenopausal and menopausal people are prescribed HRT despite these guidelines stating that for the majority of women the benefits of HRT outweigh any risks.

It is estimated that around 75% of menopausal women experience symptoms and around 25% of women experience severe symptoms that have a negative effect on their lives, often affecting their family and performance at work.

The vasomotor symptoms of the menopause are the ones that are most obvious when thinking about menopause, but these are not the symptoms that affect women the most. It is the symptoms of low mood, anxiety, reduced self-esteem, poor memory and concentration, reduced libido, joint pains and vaginal dryness that usually affect women and some non-binary people the most.

# Benefits and risks of HRT

There are numerous potential benefits to be gained by women taking HRT. Symptoms of the menopause such as hot flushes, mood swings, night sweats, and reduced libido improve. In addition, taking HRT has also been shown to reduce future risk of cardiovascular disease, osteoporosis, type 2 diabetes, osteoarthritis and dementia<sup>4-6</sup>. Most benefit is afforded when women start HRT within 10 years of their menopause. HRT can

be given to perimenopausal women and then continued for as long as benefits outweigh the risks (usually for ever). Older women who start HRT usually also gain benefit.

The type of HRT also affects a woman's benefits and risks. HRT containing micronised progesterone is associated with a lower risk of breast cancer, cardiovascular disease, and thromboembolic events compared with synthetic progestogens<sup>7-8</sup>. In addition, the mode of delivery of estrogen is also important because, in contrast with oral estrogen, transdermal estrogen is not associated with an increased risk of venous thromboembolism (VTE).

Most women and healthcare professionals are concerned about the possible risks of breast cancer in women taking HRT. However, the risk is far lower than many realise. Women who take estrogen only HRT (women who have had a hysterectomy) have a lower future risk of breast cancer<sup>10</sup>. Women who take estrogen and a progestogen who are over 51 years old may have a small increased risk of breast cancer. However, this increased risk is a lower magnitude to the risk of breast cancer for women who are overweight or drinking a glass or two of wine each night. Telling them this often really helps to put this risk into perspective. This risk with synthetic progestogens has not been shown to be statistically significant in any studies. Studies have shown that women who take micronised progesterone have an even lower risk of breast cancer than other women who take other progestogens. There has not been a good quality study showing that there is a risk of breast cancer at all in women who take estrogen with micronised progesterone.

Women with a history of cancer can still take HRT safely, in most cases. Many cancers are not hormone dependent, including cancers of the cervix, vagina, vulva, malignant melanoma and bowel. Most types of endometrial and ovarian cancer are also not hormone dependent. Women with a family history of cancer — including breast cancer — can still take HRT.

There is no good evidence regarding giving HRT to women with a history of an estrogen receptor positive cancer. Some women with a history of these cancers choose to take HRT for the health benefits and improvements to the quality of their lives. Women with estrogen receptor negative cancers can usually take HRT.

---

## How to prescribe HRT: Firstly - keep it simple

There is robust evidence demonstrating that transdermal estrogen in association with micronised progesterone represents the optimal HRT regimen, particularly in women at risk of cardiovascular events<sup>11</sup>. This combination should ideally be initiated by healthcare professionals at a primary care level.

Considerations when prescribing combination products:

- There is less flexibility if you want to alter the estrogen dose
- They all contain older progestogens, except the new combined type known as Bijuve®.

Considerations when prescribing oral estrogen first line:

- There is VTE risk with oral estrogen
- Oral estrogen increases sex hormone binding globulin (SHBG) so reducing free androgen index (lowers libido even more)
- There is less reliable absorption
- There are more contraindications (for example obesity, diabetes, gallbladder disease, migraine and so on).

# 1. The most important hormone in HRT is estrogen – best as 17 beta-Estradiol

The optimal dose for each woman should be given to improve symptoms and also to optimise bone and heart health. Women can continue taking HRT for as long as the benefits outweigh any risks, which usually means for ever. They should have an annual review.

It is NOT about lower dose and shortest length of time anymore!

Transdermal estrogen has no clot risk associated with it. It can be given to women with a history of clot and women with an increased risk of clot or stroke including women with migraines.

It can also be given to women with hypertension and cardiovascular disease.

### Patches – pros:

- Usually stick well and easy to use
- Can swim, shower, bath, swim with them on
- Constant level given so can be better in women with migraines
- Can use more than one which is useful for women with early menopause / primary ovarian insufficiency (POI) who may need higher doses.

### Gel – pros:

- Easy to alter dose so women have more control
- Usually absorb really easily
- Can be used with patches to 'top up'
- Women with cyclical symptoms (including PMS) can use more on the days with worse symptoms.

### Spray – pros:

- Light preparation and small volume
- Is absorbed easily
- Can be used with patches to 'top up'
- Women with cyclical symptoms (including PMS) can use more on the days with worse symptoms

### Patches – cons:

- Some women do not like to have something stuck to their skin
- Can lead to local irritation
- Some women find they do not stick on well or they crinkle (therefore reduced absorption)
- Some women find they have high absorption in hot climates
- Plaster mark on bottom – can be removed with baby oil and dry flannel!

### Gel – cons:

- Young women needing higher doses need to use large quantities
- Harder to remember as needed once or twice a day
- Sachets can be hard to open.

### Spray – cons:

- Young women needing higher doses need to use large quantities
- Harder to remember as needed once or twice a day
- Appears to have unreliable absorption in some women

## Commonly prescribed preparations:

- Evorel 25 / 50 / 75 / 100mcg patches, twice a week
- Estradot 25 / 50 / 75 / 100mcg patches, twice a week
- Oestrogel 2-4 pumps a day
- Sandrena gel 0.5 / 1mg sachets

Some women may choose an oral preparation or may not absorb transdermal estrogen adequately. The safest progestogen with respect to breast cancer and clot risk is dydrogesterone.

The following are the available preparations containing dydrogestodene:

- Femoston 1/10 (1mg estradiol and 10mg dydrogesterone) – cyclical preparation
- Femoston 2/10 (2mg estradiol and 10mg dydrogesterone) – cyclical preparation
- Femoston Conti 0.5/2.5 (0.5mg estradiol and 2.5mg dydrogesterone) – continuous preparation
- Femoston Conti 1/5 (1mg estradiol and 2.5mg dydrogesterone) – continuous preparation

---

### Dose Equivalents of Various Preparations

<b>Patch</b>	Half a 25 microgram patch	25 micrograms	50 micrograms	75 - 100 micrograms
<b>Gel - pump</b>	1/2 pump	1 pump	2 pumps	3 - 4 pumps
<b>Gel - sachet</b>	1/2 of a 0.5mg sachet	0.5mg sachet	1mg	1 - 2mg
<b>Spray*</b>		1-2 spray	2-3 sprays	>3 sprays

\* These doses are approximate as absorption of the spray is very variable with many women finding they need to use large quantities for symptomatic benefit.

## 2. Women with a uterus need progesterone or a progestogen too

### A few tips:

- Give cyclical HRT for first 6-12 months if they are having periods
- Continuous progestogens are better for endometrial protection
- Any age woman can take continuous HRT but it may cause erratic bleeding if given too early

The evidence supports the use of micronised progesterone (Utrogestan) as the most favourable progestogen. Can be prescribed cyclically, 200mg each evening, for 2 out of 4 weeks OR continuously, 100mg each evening. The dose can be increased (to 200mg each evening) if women are experiencing breakthrough bleeding with the continuous dose of 100mg.

### Pros:

- Fewer side effects so better tolerated
- Can improve cardiovascular risk / lipids
- Neutral effect on BP / may reduce BP
- No VTE risk
- No good quality evidence it increases breast cancer risk
- Studies have shown some positive effect on bone strength
- Can often reduce anxiety
- Can be used vaginally (off license) usually at half the oral dose in women who cannot tolerate oral progesterone
- Can be considered by some as a contraceptive, if taken continuously and no periods (off license)

### Cons:

- Can result in more breakthrough bleeding than synthetic progestogens
- Can cause some sedation — is taken at night time (though many women like this side effect). Needs to be taken on an empty stomach (eating food increases absorption, however this is not detrimental)
- Not licensed as a contraceptive

If Utrogestan is not available or not tolerated then consider Evorel Conti / Evorel Sequi (50mcg estradiol). Many women need additional estradiol which can be given as an estradiol patch or as the gel or spray.

## Mirena Coil (IUS)

### Pros:


- Contraception
- Less risk of bleeding
- Can be safely used for 5 years as endometrial protection as recommended by FSRH<sup>12</sup> (actually licensed for 4 years)

### Cons:

- Systemic side effects can occur in first 3-6 months
- Spotting and irregular bleeding can occur in first 3-12 months
- Not every woman's choice
- Sometimes difficult to access because of local commissioning arrangements

---

Using estrogen as a patch or gel and micronised progesterone is cheap for the NHS (price per month):



Clearly HRT is only one part of the management of perimenopausal and menopausal women.

Lifestyle recommendations regarding diet, exercise, smoking cessation, and safe levels of alcohol consumption should be encouraged.

## 3.

# Testosterone is often beneficial

Adding testosterone to HRT can improve sexual function and general wellbeing. Testosterone can improve libido<sup>13</sup>. In addition, testosterone can improve mood, energy, stamina and concentration. Many women notice that their brain fog and memory improve.

A significant problem with prescribing testosterone is that there are currently no available licensed preparations for women in the UK. GMC guidance on the prescription of unlicensed medication should be consulted when prescribing. It is important to ensure that women are adequately estrogenised before adding in testosterone; this is usually the case when they are no longer experiencing vasomotor symptoms.

Blood results are a guide and are not a reliable way of assessing need for testosterone.

It can sometimes take several weeks, even months for a woman to notice the beneficial effects of testosterone. If they have not noticed an improvement after six months, then it is unlikely to be beneficial. Clinical improvement in symptoms is more important than aiming for a specific level on treatment.

- Baseline blood tests are optional as most women will have low testosterone and FAI – treatment is based on symptoms
- Ensure no other cause for her symptoms
- Ensure the woman does not have a specific treatable cause for her low FAI (e.g. oral estrogens)

### Commonly used testosterone replacement for women:

- Testogel® (1% testosterone gel in 5g sachets, containing 50mg testosterone): Starting dose 1/10 of a sachet/day = 5mg/day i.e. each sachet should last 10 days.
- Testim® (1% testosterone gel in 5g tubes, containing 50mg testosterone): Starting dose 1/10 of a tube/day = 5mg/day i.e. each tube should last 10 days.
- AndroFeme® (1% testosterone cream in 50ml tubes with screw cap, only available privately): Starting dose 0.5ml/day = 5mg /day i.e. each tube should last 100 days.



## Vaginal estrogens

Although vaginal estrogen is not actually HRT it is important to know the following:

- Vaginal estrogen is safe to give with HRT (about 20% of women need both).
- Vaginal estrogen can be given as a pessary, cream, gel or vaginal ring.
- Vaginal estrogen should be prescribed in the long term (i.e. on repeat prescriptions).
- The dose of vaginal estrogen is very low (using 10mcg estrogen pessaries regularly for one year is an equivalent dose to just one 1mg estradiol HRT tablet).
- Women with a history of any type of cancer, including an estrogen receptor positive cancer, can still safely use vaginal estrogen and continue using this in the long term<sup>14</sup>.
- Evidence does not show an increased risk of cancer recurrence among women currently undergoing treatment for breast cancer, or those with a personal history of breast cancer, who use vaginal estrogen to relieve urogenital symptoms.
- GPs and primary care healthcare professionals can safely prescribe vaginal estrogen.
- Theoretically, women taking aromatase inhibitors should not use vaginal estrogen preparations, however, these preparations can still usually be given to these women and they can really have a beneficial effect on their localised symptoms.
- Many women using vaginal estrogen should also be recommended to use non-hormonal vaginal moisturisers and lubricants too.

Intravaginal (prasterone) is a daily pessary treatment containing DHEA (dehydroepiandrosterone) and is converted intracellularly to androgens and estrogens. It has been shown to be associated with improvements in symptoms without significant changes in serum estrogen or androgen levels.

*Useful resource: **British Society for Sexual Medicine (2021) Position Statement for Management of Genitourinary Syndrome of the Menopause (GSM) Authors: Dr L Newson, Prof M Kirby, Dr S Stillwell, Prof G Hackett, Dr S Ball, Dr R Lewis***

## References

- 1 National Institute for Health and Care Excellence. NICE guideline NG23 – Menopause: diagnosis and management 2015 [May 2017]. Available from: <https://www.nice.org.uk/guidance/ng23>
- 2 Baber RJ, Panay N, Fenton A, Group IMSW. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric* 2016;19:109-150
- 3 Hamoda H, Panay N, Pedder H, Arya R, Savvas M. The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. *Post Reproductive Health* 2020, Vol. 26(4) 181–208
- 4 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-333
- 5 Manson JE, Aragaki AK, Rossouw JE et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. *JAMA*. 2017; 318(10):927-938
- 6 Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev* 2015:CD002229
- 7 Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. *Climacteric*. 2018 Apr;21(2):111-122. M.
- 8 L'Hermite. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. *Climacteric* 2017; 20:331-338
- 9 Newson L, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. *BJGP* 2018; 68: 499-500.
- 10 Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. *JAMA*. 2020 Jul 28;324(4):369-380
- 11 Vinogradova Y, Coupland C, Hippisley-Cox J Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ* 2019;364:k4810
- 12 Contraception for women aged over 40 <https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017/>
- 13 Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. *Lancet Diabetes Endocrinol*. 2019 Oct;7(10):754-766.
- 14 The use of vaginal estrogen in women with a history of estrogen dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016; 127:e93–96.



The Newson Health Menopause Society was launched in 2022 to improve the experience and future health outcomes of all affected by the perimenopause and menopause, around the world.

The society is a multidisciplinary collective of healthcare professionals and experts who are passionate about improving women's health and researching the role of hormones in disease prevention and future health.

Associates of the society are supported through professional development and networking, connected and empowered in research and provided with practical advice and guidance to improve health outcomes for people in the perimenopause and menopause around the globe.

To become an associate of the Newson Health Menopause Society, visit [www.nhmenopausesociety.org](http://www.nhmenopausesociety.org)

 **@NHmenoSociety**

 **Newson Health Menopause Society**

This guidance has been written to help improve understanding of the menopause. No pharmaceutical companies contribute to the cost of providing this education, nor do they have any input into, or control over, the content of this work. The information provided is designed to support, not to replace, the relationship that exists between a patient and their healthcare professional.

---

© Newson Health Research and Education 2022

All intellectual property rights in the content and materials in this leaflet are owned by Newson Health Research and Education. Materials, images and other content may not be copied without the express prior written permission or licence of Newson Health Research and Education.